Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t ...

Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).

Think of the bone marrow as the body’s factory for blood and immune cells. In myelodysplastic syndromes (MDS), that factory breaks down—producing too few cells, and the ones that do roll off the line ...

Tobacco smoking is linked to specific genetic mutations in MDS, affecting chromatin modification and RNA splicing pathways. A dose-response relationship exists, with higher smoking intensity ...

Researchers in the Landau lab, led by Dr. Dan Landau, hematology and medical oncology, recently developed a new technique to investigate how mutations in RNA splicing can lead to clonal hematopoiesis ...